MannKind Financial Ratios
NASDAQ: MNKDHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.29-0.13 (-3.80%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
MannKind ratio analysis
MannKind earned a net margin of 1.7% in FY 2025, down from 9.7% a year earlier. Gross margin was 92.3% compared with a median of 77.7% over the prior 9 years. At the end of FY 2025, MNKD traded at 280.0 times earnings; across the 3 fiscal years shown, its year-end P/E ranged from 2.4 to 280.0, with a median of 64.8.
Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
MannKind financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 280.00 | 64.80 | — | — | — | — | — | — | — | 2.35 |
| Price / sales | 4.90 | 6.23 | 4.89 | 13.58 | 14.44 | 10.69 | 3.94 | 6.11 | 20.59 | 1.69 |
| Gross margin | 92.3% | 93.9% | 89.5% | 84.0% | 77.7% | 76.8% | 68.1% | 30.4% | -46.7% | 90.2% |
| Operating margin | 11.1% | 25.4% | 4.4% | -64.3% | -62.3% | -73.5% | -70.7% | -274.9% | -921.1% | 38.5% |
| Net margin | 1.7% | 9.7% | -6.0% | -87.6% | -107.3% | -87.9% | -82.3% | -312.2% | -999.0% | 71.9% |
| Free cash flow margin | 3.9% | 11.5% | -4.2% | -88.5% | -97.0% | -44.4% | -144.4% | -136.7% | -551.5% | -45.3% |
| Return on assets (ROA) | 0.7% | 7.0% | -2.5% | -29.6% | -25.2% | -52.7% | -55.4% | -80.8% | -138.7% | 117.4% |
| Current ratio | 1.70 | 3.28 | 3.59 | 3.49 | 4.54 | 1.08 | 0.93 | 1.09 | 0.65 | 0.84 |
| Revenue growth | 22.2% | 43.5% | 99.4% | 32.2% | 15.8% | 3.3% | 126.3% | 137.2% | -93.3% | — |
| EPS growth | -80.0% | — | — | — | — | — | — | — | -183.1% | — |